Cetuximab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9499 publications

Multi-agent chemotherapy for refractory head and neck cancer.

Multi-agent chemotherapy for refractory head and neck cancer.

Journal: Journal of the Chinese Medical Association : JCMA

Published: January 08, 2026

A Case of Severe Skin Adverse Reactions Caused by Cetuximab.

A Case of Severe Skin Adverse Reactions Caused by Cetuximab.

Journal: Journal of visualized experiments : JoVE

Published: January 06, 2026

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Journal: Molecular cancer

Published: December 30, 2025

Quality by design (QbD) approach to SE-HPLC method development for cetuximab Monoclonal antibodies.

Quality by design (QbD) approach to SE-HPLC method development for cetuximab Monoclonal antibodies.

Journal: Preparative biochemistry & biotechnology

Published: December 22, 2025

Clinical study on induction chemotherapy combined with concurrent chemoradiotherapy for oropharyngeal squamous cell carcinoma

Clinical study on induction chemotherapy combined with concurrent chemoradiotherapy for oropharyngeal squamous cell carcinoma

Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Published: December 10, 2025

The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database.

The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: December 09, 2025

Pharmacist-Led Prevention of Recurrent Cetuximab Infusion Reactions.

Pharmacist-Led Prevention of Recurrent Cetuximab Infusion Reactions.

Journal: Cureus

Published: November 25, 2025

Retrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer-Experience of Two Polish Comprehensive Cancer Centers.

Retrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer-Experience of Two Polish Comprehensive Cancer Centers.

Journal: Journal of clinical medicine

Published: November 16, 2025

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer.

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer.

Journal: Future oncology (London, England)

Published: November 13, 2025

Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies.

Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies.

Journal: Biomedicines

Published: November 05, 2025

Redox-driven FABP1/PPARγ signaling fuels peroxisomal fatty acid oxidation and confers cetuximab resistance in drug-tolerant head and neck cancer cells.

Redox-driven FABP1/PPARγ signaling fuels peroxisomal fatty acid oxidation and confers cetuximab resistance in drug-tolerant head and neck cancer cells.

Journal: Free radical biology & medicine

Published: November 04, 2025

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 04, 2025

Showing 1-12 of 9,499

Last Updated: 02/24/2026